Health Includes Body and Soul - Possibilities in Hungary

Firstly, i must confess honestly recently i hadnt had enough
time to post new and attracting stuffs. But, now, i decided that
it would be benign if we take a trip in the sphera of the therapy
process, methods to discover how can people ease their
pain with the newest and classics therapy-methods.

Im just about to bolster another blogger's theme. Because our
first visit has taken place in Hungary, especielly in its most notable
therapy and spa centrum, Hajdúszoboszló. Do not hesitate and click on the mentioned name to widen mind in the light of this theme.

As we know the therapeutics has got some scope in wide range. From the healthy hot springs through the pleasure park, where are some provided speciel processes which facilitate the tranquil healing up. Hungary has a lot of opportunities out of these, one of the biggest favoured place is Hajduszoboszlo. Make a little ad for it, it is a must, but, it is without any capitalization goals, its a pure object, to make greater renown for this health paradise, for the sake of people.

Are we close ties with God?

"God has not given us any disease for which he has not provided a remedy." Paracelsus

I have been crawling and surfing on the Internet, and at last bumped into a very gripping
doctor of TCM thesis by Ricardo Serrano, entitled: Cure and Cause of Cancer is Within You.

"The cure and cause of cancer is within you. The cause of cancer is a weakening of your immune system (Wei Qi) which is termed Chronic Immune (Wei) Dysfunction Syndrome (CIDS). I will elaborate more on this theory at the Cause web page and you will know why Traditional Chinese Medicine works.

The cure for cancer is strengthening your immune system (Wei Qi) which can be done naturally with powerful tools such as herbal formulas (detoxification and nourishment), meditation, acupuncture/moxibustion, pranic healing, and nutritional supplementation in an integrated manner. I will elaborate more on this at the Cure web page.

My theories and system of cure is rational, time tested and scientifically proven for centuries according to Traditional Chinese medical theory on strengthening Wei Qi as practiced in mainland China and everywhere in the world.

I believe that Our Creator provides us with powerful tools from nature and within us to deal with our health challenges as long as we have faith in the healing power within ourselves and use Mother Earth's herbs and special foods."

He looks convincing, its time to be hopeful mankind's ability is enough to reveal all causes of cancers by and by. As im concerned: im flurried.

Cancer Research a'la hungarian method

Huge hungarian achievement in cancer research

Professor Istvan Majoros' invention named dendrimer can devour directly the sick cells.

It will be the biggest performance in the story of the hungarian cancer research if the artificial dendrim molecule adaptable on people too.


 
According to the erudite the cell can be treated as trojan woodhorse able to dispatch some medicine to the cancered cells, which annex it - in the hope of the important vitamines - whereby the traditional kemotherapy might be readily superfluos.

The new method can only deploy for the treatment of the evolved cancer, in turn its dosing can be revised by prefrences, and it has not got any spillover.

The professor who lives in USA since 1990 is trusting in connection with the application of the new developed method, he said, in the course of animal tests they destroyed the breast-cancer successfully. At this moment the animal attempts are going, and the deploying of the new dendrin is likely to be a grave counterpart, and cope with whatever cancer types.

The discovery was welcomed keenly by the profession, for example Michigan subsidies the professor's research with notable sum of money. Istan Majoros said, all terms are available in the United States to the research, however, there are very stringent yearly probes, in which the researcher groups are examined, and make the subsidies in line with the achievements.

Istvan Majoros added the sick people are the most important for himself than the money, he tries to do his best in order to rise the quality level of the Hungarian cancer research.

The Cost of Developing a New Drug

This particular column stems from the CBO's Study, named: Research and Development in the Pharmaceutical Industry - i would like to express my satisfaction and happiness in connection with this study, read it because it is advisable:

Research and development costs vary widely from one new drug to the next. Those costs depend on the type of drug being developed, the likelihood of failure, and whether the drug is based on a molecule not used before in any pharmaceutical product (a new molecular entity, or NME) or instead is an incremental modification of an existing drug.

Innovative Drugs
A recent, widely circulated estimate put the average cost of developing an innovative new drug at more than $800 million, including expenditures on failed projects and the
value of forgone alternative investments.1 Although that average cost suggests that new-drug discovery and development can be very expensive, it reflects the research strategies and drug-development choices that companies make on the basis of their expectations about future revenue. If companies expected to earn less from future drug sales, they would alter their research strategies to lower their average R&D spending per drug. Moreover, that
estimate represents only NMEs developed by a sample of large pharmaceutical firms. Other types of drugs often cost much less to develop (although NMEs have been the source of most of the major therapeutic advances in pharmaceuticals).

The study that produced that cost estimate also calculated how long it takes to develop a new drug and the relative contribution of capital costs to a drug’s total R&D costs. On average, developing an innovative new drug takes about 12 years, the study concluded, and a firm’s actual expenditures make up only about half of the total reported cost. The rest represents the financial cost of tying up investment capital in multiyear drugdevelopment
projects, earning no return until and unless a project succeeds. That “opportunity cost” of capital reflects forgone interest or earnings from alternative uses of the capital. (Opportunity costs are common to all innovative industries, but they are particularly large for pharmaceutical firms because of the relatively long time that is often required to develop a new drug.)

Research and development spending per NME has grown significantly in recent years, for various reasons. First, failure rates in clinical trials have increased, possibly because
of greater research challenges or a willingness to test riskier drugs in such trials. Second, larger drug firms are said to have shifted the focus of their development efforts away from drugs for acute illnesses and toward drugs for chronic illnesses. Drugs that treat chronic illnesses can be more expensive to develop because they often require larger and longer clinical trials. Third, greater technological complexity in drug development and greater specificity in disease targets have helped to raise average R&D costs, as firms now identify drugs with particular molecular characteristics rather than using trial-and-error methods
to find compounds that work in some desired way. Not all new molecular entities provide unique therapeutic functions. Many NMEs are so-called “me-too” drugs. Despite that name, they are not necessarily imitations of other drugs. Rather, they may be innovative products that lost the race to be the first drug on the market in a given therapeutic class (such as antidepressants, antibiotics, or antihistamines). Such products can benefit consumers by
competing with, and sometimes improving on, the pioneering drug in a class.

Facility of the year - hip hip drugsah!

2007 Facility of the Year Award Category Winners Announced

Five pharmaceutical manufacturing facilities located in China, Germany, Japan, and the United States have been selected as Category Winners in the third annual Facility of the Year Awards competition sponsored by ISPE, INTERPHEX, and Pharmaceutical Processing magazine. New enhancements to this year’s awards program include naming winners in five specific categories.

The companies and respective award categories include:
* Cook Pharmica, LLC, located in Bloomington, Indiana, USA, selected as winner of the Facility of the Year Award for Facility Integration
* Genentech located in Oceanside, California, USA, selected as winner of the Facility of the Year Award for Project Execution
* Shanghai Roche Pharmaceuticals, Ltd., located in Shanghai, China, selected as winner of the Facility of the Year Award for Project Execution Regional Excellence
* Taiyo Yakuhin Co., Ltd located in Takayama City, Japan, selected as winner of the Facility of the Year Award for Equipment Innovation
* Vetter Pharma-Fertigung GmbH & Co. KG located in Ravensburg, Germany, selected as winner of the Facility of the Year Award for Process Innovation

The Facility of the Year Awards competition is the premier global awards program focused on recognizing the innovation and creativity utilized by manufacturing facilities serving the regulated health care industry. By recognizing those manufacturers who are using new technologies both to improve the quality of their products while reducing the cost of producing medicines, the awards program promotes technological innovation across the industry. In consideration that the product development and research aspects of the pharmaceutical manufacturing industry generally get most of the attention, the Facility of the Year Awards program recognizes those who design, build, and operate world-class manufacturing facilities.

Being named a Category Winner generates unsurpassed opportunities for the applicant manufacturer and those organizations that designed, constructed, validated, and equipped the facility to showcase their ingenuity in facility design through various publicity initiatives. Moreover, the competition offers an unprecedented opportunity for submitting companies, category winners, and the Facility of the Year Award winner to motivate colleagues within the industry toward these advances through the sharing of industry-wide best practices within the global community.

“There is something truly remarkable and innovative about every single submission,” said Scott Ludlum, ISPE's Director of Business Initiatives. “
The five Category Winners hail from four different countries. This diversity demonstrates that the Awards program is a true reflection of the global nature of the pharmaceutical manufacturing industry,” said Ludlum.

Each of the submissions was reviewed by an independent, blue-ribbon judging panel of global representatives from the pharmaceutical design, construction, and manufacturing sectors.
“The addition of Category Winners to the 2007 Awards program significantly impacted the competition and effectively enabled the judges to properly acknowledge those facilities that stood out and deserve special recognition,” stated Andy Skibo, 2007 Judging Panel Chair, and Vice President Corporate Engineering and Capital Projects for Amgen.

Recognition at INTERPHEX

2007 Category Winners will be recognized and awarded during INTERPHEX2007, where thousands convene for the largest and most distinguished industry event taking place worldwide, which takes place from 24-26 April 2007.

The announcement of the coveted Facility of the Year Awards winner will take place at ISPE’s 2007 Annual Meeting in November at Caesars Palace in Las Vegas. ISPE’s Annual Meeting is the leading industry event attended by pharmaceutical manufacturing professionals where Category Winners will be recognized in front of their peers during ISPE’s keynote session. There will also be a separate Facility of the Year Awards display and a conference session featuring the Category Winners and Facility of the Year Award Winner.

Meet the 2007 Facility of the Year Judging Panel

Andy Skibo Judging Panel Chair VP Corp. Engineering and Capital Production Amgen
Nigel Barnes Vice President, Global Project Management GlaxoSmithKline.
Chaz Calitri Senior Director/Team Leader Pfizer Global Engineering
Christian Ilsoe Vice President Quality & Validation Assurance NNE A/S
Brian H. Lange, P.E. Director – Sterile & Packaging Operations Engineering Merck & Co., Inc.
Thomas G. Lyon Vice President Global Engineering Bristol Myers Squibb Co.
Shinichi Osada Chief Marketing Manager Hitachi Plant Technologies, Ltd.
Ulrich Rudow VP Worldwide Engineering and Real Estate Johnson & Johnson
Ronald Trudeau Vice President – Facilities Engineering Services Baxter Healthcare Corp.

Please, let me congratulate to winnwers, and express my profoundly appreciation.

Over The Counter Market

Over-the-counter medicines

The circulation having many of those medicines, which are available without prescriptions. The market of this medicines is called over-the-counter (OTC). The purchase of the OTC's articles are being treated as self-healing method, at least from the view of the doctor society. Besides, obviously it has a lots of perils. The OTC-articles - contrary to the medicines are subject to prescription - can be widely advertised.




Four advantages of the OTC:

- there are no need high-cost meetings of the doctor-patient
- generally, the health insurances do not support this medicines (this means: savings)
- this market can boost the good will of pharmacists
- can boost the health awareness of the people, the own responsibilities of the own health state

Accordint to the date of 1998, the OTC's medicines' turnover was $75 billion. The data shows that the reacher countries are spending more than the poorer.

Global Medicine Market Has Slightly Accelerated In 2006

According to the estimates of the last year throughout the World the value of the sold article of the chemists was 643 billion $, and it eclipsed the former value with 7 percentage – coming to light from the last released analysis of the IHS.

The measure of the medicine consumption is rising by far the biggest value: for instance it was 13 percantage in Latin-American region, and the market expanded with tenth in the Asian, African region.

In China, the market expansion showed a little deceleration: the market grew with eighth, it was a backlog compared with the last years.

The turnover of the pharmaceutical articles raised with 8,3 percantage in the U.S, it was the greatest value among the developed countries, due to the adjustment of the financial system.
In Europe the market has been slowing further, due to the gaining upon of the generic medicine.
The consumption was damping nearly 1 percant in Japan.

As for the product lines, the cholesterol-reducing, fatty acid controller are in greatest demand, in last year, they are purchased in 35,2 billion $ throughout the World.

Gold Age Of The Pharmaceutical Industry

According to the analists, the gold age of the pharmaceutical industry was between 1955 and 1985, but nowdays there are similar opportunities in this ramification. The mentioned date of the gold age can be described the following attributes:

- permanent growing market
- increasingly discovers of the new molecules
- full patent protection over the staple markets
- minimum 5 years monopol situation due to the breakthrough drugs
- slowly emerging of the generic markets
- almost full pricing independence in utmost markets
- good defined consumer market

The World Biggest Pharmaceutical factories in 1999

Firm Name and Annual Turnover (billion $)
1. Pfizer ( _23,15_ )
2. GlaxoSmithKline (_ 22,04_ )
3. AstraZeneca ( _14,29_ )
5. Bristol-Myers Squibb ( _13,28_ )
6. Novartis ( _12,41_ )
7. Johnson & Johnson ( _12,36_ )
8. Aventis ( _11,31_)
9. Pharmacia ( _10,25_ )
10. American Home Products ( _9,57_ )